Axsome Therapeutics Reports P-III Results of AXS-12 for the Treatment of Narcolepsy
Read More: Axsome Therapeutics
SELLAS Reports P-IIa Results of SLS009 for the Treatment of Acute Myeloid Leukemia (AML)
Read More: SELLAS
Novocure Reveals the P-III (METIS) Study Results of Stereotactic Radiosurgery in NSCLC Patients
Read More: Novocure
Immuneering Doses First Patient with IMM-6-415 in the P-I/IIa Clinical Evaluation for Treating Advanced Solid Tumors
Read More: Immuneering
BMS Reveals Data from the P-III (KRYSTAL-12) Trial of Krazati as a Treatment of Non-Small Cell Lung Cancer
Read More: BMS
InnoCare Doses First Patient with ICP-189 in the P-Ib Clinical Evaluation to Treat Non-Small Cell Lung Cancer
Read More: InnoCare
The US FDA Grants Approval to Johnson & Johnson’s Opsynvi (macitentan and tadalafil) for the Treatment of Pulmonary Arterial Hypertension
Read More: Johnson & Johnson
The US FDA Grants Approval to Merck’s Winrevair (sotatercept-csrk) for the Treatment of Pulmonary Arterial Hypertension (PAH)
Read More: Merck
The US FDA Grants Approval to AstraZeneca’s Ultomiris (ravulizumab-cwvz) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Read More: AstraZeneca
The MHLW Grants Approval to Takeda’s Adzynma (apadamtase alfa/cinaxadamtase alfa) for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Read More: Takeda
The NMPA Accepts HUTCHMED’s sNDA for Savolitinib to Treat NSCLC Associated with MET Exon 14 Mutations
Read More: HUTCHMED
The EC Approves Merck’s Keytruda Combined with Chemotherapy for Treating Non-Small Cell Lung Cancer
Read More: Merck
The NMPA Accepts Astellas and Pfizer’s sBLA for Enfortumab Vedotin Plus Keytruda for Treating Bladder Cancer
Read More: Astellas & Pfizer
AbbVie Acquires Landos Biopharma for an Aggregate of $212.5M
Read More: AbbVie & Landos Biopharma
Novo Nordisk Acquires Cardior Pharmaceuticals for an Aggregate of ~$1.11B
Read More: Novo Nordisk & Cardior Pharmaceuticals
Juvisé Pharmaceuticals Acquires Actelion’s Ponvory (ponesimod) for the Treatment of Multiple Sclerosis (MS)
Read More: Juvisé Pharmaceuticals & Actelion Pharmaceutical
Verge Genomics Enters into a Collaboration Agreement with Ferrer for the Development and Commercialization of VRG50635 to Treat Amyotrophic Lateral Sclerosis (ALS)
Read More: Verge Genomics & Ferrer
ABVC BioPharma and ForSeeCon Eye Corporation (FEYE) Entered into a Global Licensing Agreement for the Development and Commercialization of Various Ophthalmology Products
Read More: ABVC BioPharma & ForSeeCon Eye Corporation
Primrose Bio and Intravacc Join Forces to Develop Conjugate Vaccine
Read More: Primrose Bio & Intravacc
GenFleet and BeiGene Join Forces to Conduct P-Ib/II Study of GFH009 and Brukinsa for Treating Diffuse Large B Cell Lymphoma
Read More: GenFleet & BeiGene
Gilead Collaborates with Xilio Therapeutics to Develop XTX301 for Treating Wide Range of Cancers
Read More: Gilead & Xilio
Health Canada Grants Approval to Innodem Neuroscience’s ETNA-MS for the Treatment of Multiple Sclerosis (MS)
Read More: Innodem Neuroscience
The US FDA Approves Medtronic’s Evolut TAVR System for the Treatment of Aortic Stenosis
Read More: Medtronic
InterSystems Collaborates with ImmunoPrecise Antibodies (IPA) to Combine the Vector Capability of Their Platforms for Healthcare Applications
Read More: InterSystems & ImmunoPrecise Antibodies
Related Post:- PharmaShots Weekly Snapshots (March 18 – March 22, 2024)
